ميمپارا
amgen europe b.v. - cinacalcet hydrochloride 30 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.
ميمپارا
amgen europe b.v. - cinacalcet hydrochloride 60 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.
ميمپارا
amgen europe b.v. - cinacalcet hydrochloride 90 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.
norages 2 mg/ml iv 10 ampolles 4 ml
mentis 300 mg 60 càpsules
mentis 300 mg 24 càpsules
vaselina mentolada orravan pomada 13 g
ibucalm 5% gel mentolado 60 g
hibitane 5/5 20 comprimits per llepar mentol